Mechanism, clinical consequences, and management of dyslipidemia in children with nephrotic syndrome

키워드

참고문헌 (47)

1. Larkins NG, "Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children", Cochrane Database Syst Rev, 4, pp.CD002290~ (2020)
2. 강희경, "Nephrotic syndrome: what’s new, what’s hot?", Clinical and Experimental Pediatrics, 58(8), pp.275~282 (2015), 대한소아청소년과학회
3. Agrawal S, "Dyslipidaemia in nephrotic syndrome : mechanisms and treatment", Nat Rev Nephrol, 14, pp.57~70 (2018)
4. Vaziri ND, "Disorders of lipid metabolism in nephrotic syndrome : mechanisms and consequences", Kidney Int, 90, pp.41~52 (2016)
5. Vaziri ND, "Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression", Clin Exp Nephrol, 16, pp.238~243 (2012)
6. Sato T, "Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis", Kidney Int, 61, pp.157~162 (2002)
7. Liu S, "Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome", Nephrol Dial Transplant, 29, pp.538~543 (2014)
8. Morris AW, "Nephrotic syndrome : PCSK9 : a target for hypercholesterolaemia in nephrotic syndrome", Nat Rev Nephrol, 12, pp.510~ (2016)
9. Jin K, "Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis : a cross-sectional study", Am J Kidney Dis, 63, pp.584~589 (2014)
10. Moorhead JF, "Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease", Lancet, 2, pp.1309~1311 (1982)
11. Clement LC, "Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome", Nat Med, 20, pp.37~46 (2014)
12. Vaziri ND, "Up-regulation of acyl-coenzyme A : cholesterol acyltransferase(ACAT)in nephrotic syndrome", Kidney Int, 61, pp.1769~1775 (2002)
13. Vaziri ND, "Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome", Circulation, 110, pp.419~425 (2004)
14. Vaziri ND, "Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis", Kidney Int, 48, pp.1979~1985 (1995)
15. Vaziri ND, "Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis", Kidney Int, 63, pp.1756~1763 (2003)
16. Ordonez JD, "The increased risk of coronary heart disease associated with nephrotic syndrome", Kidney Int, 44, pp.638~642 (1993)
17. Mehta A, "Carotid intima media thickness in children with nephrotic syndrome : an observational case control study", Sudan J Paediatr, 19, pp.110~116 (2019)
18. Radhakrishnan J, "The nephrotic syndrome, lipids, and risk factors for cardiovascular disease", Am J Kidney Dis, 22, pp.135~142 (1993)
19. Gyebi L, "Lipid nephrotoxicity : new concept for an old disease", Curr Hypertens Rep, 14, pp.177~181 (2012)
20. Chung JJ, "Albumin-associated free fatty acids induce macropinocytosis in podocytes", J Clin Invest, 125, pp.2307~2316 (2015)
21. Allison SJ, "Podocyte biology : free fatty acid-induced macropinocytosis in podocytes", Nat Rev Nephrol, 11, pp.386~ (2015)
22. Eddy AA, "Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis", Kidney Int, 33, pp.14~23 (1988)
23. Eddy AA, "A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome", Am J Pathol, 138, pp.1111~1123 (1991)
24. Cases A, "Dyslipidemia and the progression of renal disease in chronic renal failure patients", Kidney Int Suppl, (99), pp.S87~S93 (2005)
25. D’Amico G, "Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome", Lancet, 339, pp.1131~1134 (1992)
26. Gentile MG, "Treatment of proteinuric patients with a vegetarian soy diet and fish oil", Clin Nephrol, 40, pp.315~320 (1993)
27. Hall AV, "Omega-3 fatty acid supplementation in primary nephrotic syndrome : effects on plasma lipids and coagulopathy", J Am Soc Nephrol, 3, pp.1321~1329 (1992)
28. Bell S, "The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria", Clin Nephrol, 77, pp.445~453 (2012)
29. Rabelink AJ, "Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome", Lancet, 2, pp.1335~1338 (1988)
30. Thomas ME, "Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria", Kidney Int, 44, pp.1124~1129 (1993)
31. Wheeler DC, "Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment", Am J Kidney Dis, 23, pp.331~346 (1994)
32. Massy ZA, "Lipid-lowering therapy in patients with renal disease", Kidney Int, 48, pp.188~198 (1995)
33. Kong X, "Lipid-lowering agents for nephrotic syndrome", Cochrane Database Syst Rev, (12), pp.CD005425~ (2013)
34. Brown CD, "Reduction of lipoprotein(a)following treatment with lovastatin in patients with unremitting nephrotic syndrome", Am J Kidney Dis, 26, pp.170~177 (1995)
35. Khurana M, "Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease", Pediatr Nephrol, 30, pp.2073~2084 (2015)
36. Coleman JE, "Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood", Pediatr Nephrol, 10, pp.171~174 (1996)
37. Sanjad SA, "Management of hyperlipidemia in children with refractory nephrotic syndrome : the effect of statin therapy", J Pediatr, 130, pp.470~474 (1997)
38. Groggel GC, "Treatment of nephrotic hyperlipoproteinemia with gemfibrozil", Kidney Int, 36, pp.266~271 (1989)
39. Buyukcelik M, "The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome", Turk J Pediatr, 44, pp.40~44 (2002)
40. Jacobson TA, "Myopathy with statin-fibrate combination therapy : clinical considerations", Nat Rev Endocrinol, 5, pp.507~518 (2009)
41. Valeri A, "Treatment of the hyperlipidemia of the nephrotic syndrome : a controlled trial", Am J Kidney Dis, 8, pp.388~396 (1986)
42. Di Bartolo B, "PCSK9 inhibitors in hyperlipidemia : current status and clinical outlook", BioDrugs, 31, pp.167~174 (2017)
43. Haas ME, "The role of proprotein convertase subtilisin", kexin type 9 in nephrotic syndrome-associated hypercholesterolemia, 2016, pp.134, 61~72
44. Jatem E, "Efficacy and safety of PCSK9 inhibitors in hypercholesterolemia associated with refractory nephrotic syndrome", Kidney Int Rep, 6, pp.101~109 (2020)
45. Hattori M, "A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children", Am J Kidney Dis, 42, pp.1121~1130 (2003)
46. Muso E, "Beneficial effect of LDL-apheresis in refractory nephrotic syndrome", Clin Exp Nephrol, 18, pp.286~290 (2014)
47. Raina R, "An update on LDL apheresis for nephrotic syndrome", Pediatr Nephrol, 34, pp.1655~1669 (2019)

관련 논문AI추천